Entries by Uta Mommert

PulseSight to disrupt AMD space

/in /by

<span style="mso-ansi-language:EN-GB" lang="EN-GB">PulseSight Therapeutics SAS was launched on Wednesday, backed by seed financing from Pureos Bioventures and ND Capital. The company introduces a disruptive </span><span style="mso-bidi-font-family:Aptos;mso-bidi-theme-font:minor-latin;color:#272727; mso-ansi-language:EN-US" lang="EN-US">delivery platform </span><span […]

Innate immunity merger raises €75m

/in /by

Forbion has spearheaded a €75m Series A financing in Norwegian biotech Calluna Pharma. The clinical-stage company resulted from the merger of Oxitope Pharma and Arxx Therapeutics.

Roche jumps ship on AC Immune

/in /by

<span style="mso-ansi-language:EN-GB" lang="EN-GB">Genentech, Roche’s US subsidiary, is ending its decades-long collaboration with <link https://www.acimmune.com _blank>AC Immune SA</link> after disappointing study results. It has handed the global rights to Crenezumab and […]

MS: Polpharma joins forces with Sandoz

/in /by

Polpharma Biologics SA has partnered up with Novartis subsidiary Sandoz AG to market a natalizumab biosimilar. As part of the global commercialization agreement, Polpharma Biologics will be responsible for the […]

PharmaMar moves ahead with NDA for Zepsyre

/in /by

The FDA has given the go-ahead to PharmaMar’s proposal to file for accelerated approval its New Drug Application (NDA) for lurbinectedin monotherapy for the treatment of second-line small-cell lung cancer.

Billions for the circular economy

/in /by

Together with the EIB, five of the EU’s largest national promotional banks and institutions plan to invest €10bn to accelerate the transition to a sustainable and circular economy.